Mesoblast Limited (MESO,MSB.AX) announced the acquisition of an exclusive worldwide license to a patented chimeric antigen receptor (CAR) technology platform. This innovation is designed to enhance the precision and effectiveness of Mesoblast's mesenchymal lineage stromal cell (MSC) products by improving target specificity and strengthening their immunomodulatory and tissue regeneration properties.
The company plans to integrate engineered CAR constructs into its MSC platforms, which already include the first and only FDA-approved MSC product in the United States. By genetically engineering CARs into MSCs, Mesoblast aims to substantially improve targeted homing to inflamed tissue, thereby increasing potency in treating tissue-specific inflammatory diseases.
Mesoblast obtained the exclusive rights to the CAR-MSC intellectual property developed at Mayo Clinic through the acquisition of a startup formed to advance the technology. As part of the agreement, Mayo Clinic will provide in-kind support to further develop the platform and resulting products, including GMP manufacturing activities, reinforcing Mesoblast's competitive position in next-generation cell therapies.
MSB.AX was trading at A$2.18 up A$0.17 or 8.48%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.